Ulsan, South Korea

Jung-Min Kee

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Princeton University. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jung-Min Kee. Retrieved from https://idiyas.com/inventor/jung-min-kee-tj78bpjp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jung-Min Kee, Inventor in Ulsan, South Korea.

Introduction

Jung-Min Kee is an inventor associated with Ulsan, South Korea, and Princeton University. His listed patent work concerns phosphohistidine mimetics and antibodies.

Latest Patents

The provided information lists one patent for Kee: “Phosphohistidine Mimetics and Antibodies to Same.” The invention describes phosphonopyrazole-based phosphohistidine analogs that can serve as haptens for preparing immunogens. It also covers immunogens made by linking the haptens to carrier molecules, antibodies to those immunogens, and uses of the haptens, immunogens, antibodies, and phosphohistidine analogs. The record lists 1 patent.

Career Highlights

Kee’s listed patent work is connected with Princeton University. The patent focuses on tools for preparing and using antibodies that recognize phosphohistidine-related structures.

Collaborations

The provided information names Tom W. Muir and Rob C. Oslund as Kee’s coworkers.

Conclusion

Jung-Min Kee’s listed invention centers on phosphohistidine analogs and antibody-related applications, reflecting research associated with Princeton University.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…